Meeting
2024 ASCO Annual Meeting
Serum multiplex analysis of checkpoint proteins in association with immune-related adverse events in patients with melanoma receiving adjuvant anti-PD-1 therapy.
Authors
Andrew David Knight
University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA
Andrew David Knight , Sabrina Bruno , Caroline Jane Layding , Hong Wang , Cindy Sander , Walter J Storkus , Lilit Karapetyan , John M. Kirkwood
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 9588)
DOI
10.1200/JCO.2024.42.16_suppl.9588
Abstract #
9588
Poster Bd #
372
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Detection of immune-related adverse events among hospitalized patients using large language models.
First Author: Virginia H. Sun
Poster
2022 ASCO Annual Meeting
Tocilizumab in combination with ipilimumab and nivolumab in solid tumors.
First Author: Noha Abdel-Wahab
Poster
2021 ASCO Annual Meeting
Beyond steroids: Immunosuppressants in steroid-refractory/resistant immune related adverse events.
First Author: Jia Luo
Poster
2019 ASCO Quality Care Symposium
Novel clinical definitions for immune-related adverse events (irAEs): A QI intervention to improve accuracy in irAE diagnosis.
First Author: Amanda Brito